Following promises of halts to increases in drug prices in 2018, pharmaceutical makers began January by raising the prices of more than 250 drugs. Now, HHS Secretary Alex Azar is calling on companies to bring their list prices back down.
Following promises of halts to increases in drug prices in 2018, pharmaceutical makers began January by raising the prices of more than 250 drugs. Now, HHS Secretary Alex Azar is calling on companies to bring their list prices back down.
In an appearance on Fox Business Network, Azar said that “I want to be really clear to the pharma companies out there and to the pharmacy benefit managers: the president and I will not stop until list prices of drugs come down. This behavior has to stop. Drug prices must come down.”
Azar promised that the coming days would see the rollout of new regulatory and legislative proposals to address the issue of high drug prices, and that the administration would work with both Republicans and Democrats to solve the problem of price hikes.
“It’s an absolutely silly system that we have,” Azar said, to provide rebates to pharmacy benefit managers in exchange for keeping their drugs on formularies with a preferred status.
While he praised drug makers Merck, Gilead, and Amgen for lowering some list prices, he called for price cuts to more products. Azar said that “all options are on the table if they deliver solutions that keep patients at the center.”
To date, the options for driving down costs for US patients that HHS has put forth have not been eagerly embraced by the pharmaceutical industry. Among its proposals is the inclusion of list prices for drugs in advertising directed at patients, but the proposal was met with opposition from the Pharmaceutical Research and Manufacturers of America (PhRMA). The organization has said that it does not believe that CMS has authority to issue the proposed rule under existing law, and has urged HHS to rethink the policy.
However, drug maker Eli Lilly, where Azar was once an executive, has announced that it will make its pricing information more accessible to patients. In a company statement, Lilly said that it would provide pricing information online—or via a toll-free phone number—for dulaglutide (Trulicity) beginning immediately. By the end of February 2019, said the company, pricing information for other drugs that Lilly advertises on television will have similar information available online.
“We recognize that the US healthcare system has asked Americans to pay more out-of-pocket—including for prescription medicines. So people need new tools to help them,” read Lilly’s statement.
The launch of Lilly’s online pricing information follows PhRMA October 2018 release of new direct-to-consumer marketing principles that includes directing patients to “company resources may can help them with the cost of their medicine” and pointing patients to resources “where patients can find information about the cost of the medicine…including the list price and average, estimated, or typical patient-out-of-pocket costs, or other context” about the what patients will pay.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.